Results 171 to 180 of about 11,680 (228)
Efficacy of tofacitinib in the treatment of refractory palmoplantar psoriasis (non-pustular): case report and literature review. [PDF]
An Bras DermatolSakiyama PH, Miot LDB, Miot HA.
europepmc +1 more source
Effective Management of Recalcitrant Hailey-Hailey Disease With Risankizumab. [PDF]
Int J DermatolJustice J +3 more
europepmc +1 more source
FDA approves Icotyde<sup>TM</sup> (Icotrokinra): a novel IL-23 receptor antagonist for plaque psoriasis. [PDF]
Ann Med Surg (Lond)Abid MA, Abid MH, Hasan AH, Afzal MD.
europepmc +1 more source
Chromoblastomycosis: New Perspective on Adjuvant Treatment with Acitretin
Diseases (Basel, Switzerland), 2023 Chromoblastomycosis (CBM) is a neglected human disease, caused by different species of pigmented dematiaceous fungi that cause granulomatous and suppurative dermatosis.
Felipe Passero +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2014
Acitretin, a synthetic retinoid, is the pharmacologically active metabolite of etretinate. It is currently approved by the US Food and Drug Administration for the treatment of severe psoriasis in adults and has been established as a second-line therapy for the treatment of psoriasis resistant to the use of topical therapy.
Noelani E Gonzalez, Ortiz +2 more
+7 more sources
Acitretin, a synthetic retinoid, is the pharmacologically active metabolite of etretinate. It is currently approved by the US Food and Drug Administration for the treatment of severe psoriasis in adults and has been established as a second-line therapy for the treatment of psoriasis resistant to the use of topical therapy.
Noelani E Gonzalez, Ortiz +2 more
+7 more sources
Acitretin revisited in the era of biologics
Journal of Dermatological Treatment, 2011 Item does not contain fulltextAcitretin is a time-honored treatment for psoriasis. During the last decade biologics have revolutionized the treatment of psoriasis.
exaly +2 more sources
JAMA dermatology, 2023
Importance Symptomatic oral lichen planus (OLP) can be challenging to treat. Objective To compare the efficacy of oral acitretin plus topical triamcinolone acetonide (TAC), 0.1%, with TAC monotherapy in patients with symptomatic OLP. Design, Setting,
K. Vinay +6 more
semanticscholar +1 more source
Importance Symptomatic oral lichen planus (OLP) can be challenging to treat. Objective To compare the efficacy of oral acitretin plus topical triamcinolone acetonide (TAC), 0.1%, with TAC monotherapy in patients with symptomatic OLP. Design, Setting,
K. Vinay +6 more
semanticscholar +1 more source